Cell and Gene Therapy Market by Type and Geography - Forecast and Analysis 2022-2026

The cell and gene therapy market share is expected to increase by USD 9.97 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 20.15%.

This cell and gene therapy market research report provides valuable insights into the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers cell and gene therapy market segmentations by type (cell therapy and gene therapy) and geography (North America, Europe, Asia, and Rest of World (ROW)). The cell and gene therapy market report also offers information on several market vendors, including Alnylam Pharmaceuticals Inc., Amgen Inc., Biogen Inc., bluebird bio Inc., Bristol Myers Squibb Co., Castle Creek Biosciences Inc., CORESTEM Inc., Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC., Ferring BV, Gilead Sciences Inc., Helixmith Co. Ltd., Human Stem Cells Institute, JCR Pharmaceticals Co. Ltd., Kolon TissueGene Inc., Novartis AG, Orchard Therapeutics Plc, Pfizer Inc., Sibiono GeneTech Co. Ltd., and Vericel Corp. among others.

What will the Cell and Gene Therapy Market Size be During the Forecast Period?

Download Report Sample to Unlock the Cell and Gene Therapy Market Size for the Forecast Period and Other Important Statistics

 

Cell and Gene Therapy Market: Key Drivers, Trends, and Challenges

The increasing prevalence of chronic diseases is notably driving the cell and gene therapy market growth, although factors such as high cost and failure rate in clinical trials may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the cell and gene therapy industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Cell and Gene Therapy Market Driver

• The increasing prevalence of chronic diseases is one of the factors driving the cell and gene therapy market growth.
• Chronic diseases present a significant burden on patients and healthcare systems. Moreover, unhealthy lifestyle habits such as the lack of exercise, poor nutrition intake, and substance abuse such as addiction to alcohol and tobacco are the major risk factors resulting in the increasing prevalence of chronic diseases.
• The incidence of many musculoskeletal disorders and bone injuries such as arthritis, osteoporosis, and serious limb trauma injuries requiring hospitalization is increasing. For instance, in the US, many adults have arthritis and osteoarthritis.
• Most chronic diseases may result in tissue or organ damage. The vast majority of treatments available for chronic diseases are palliative. 
• A novel therapeutic approach called gene transfer involves the insertion of new genes into a cancerous cell or the surrounding tissue to cause cell death or reduce the growth of cancer. Thus, these factors will lead to the increased adoption of cell and gene therapies for the treatment of chronic diseases, which, in turn, is expected to drive the growth of the market during the forecast period.

Key Cell and Gene Therapy Market Trend

• Increasing focus on the development of drugs for emerging applications is one of the key cell and gene therapy market trends fueling the market growth.
• There has been a growing focus of vendors on developing cell therapies for emerging applications, such as oncology and musculoskeletal disorders. As there is a high unmet medical need for the treatment of such diseases, the approval of effective therapies will likely change market dynamics. 
• In oncology, there are about 36 molecules in clinical trials across all stages, among which three are in Phase III. Amgen Inc. is currently developing Blinatumomab for the treatment of B-cell non-Hodgkin lymphoma. Bluebird bio-drug candidate, LentiGlobin BB305 drug product, is currently in its Phase III development stage for the treatment of sickle cell disease.
• Many companies are extensively conducting clinical trials on autologous cell therapy products for the treatment of musculoskeletal disorders. such developments will fuel the market growth in the forecasted period.

Key Cell and Gene Therapy Market Challenge

• High cost and failure rate in clinical trials is one of the key factors challenging the cell and gene therapy market growth.
• The cost of conducting clinical trials on cell and gene therapy is high. The high cost may be attributed to the high regulatory requirements, which come with added costs.
• Multiple clinical trials need to be conducted to test biodistribution, appropriate dosing, delivery timing, tumorigenicity associated with the administered stem cells, and immune rejection. Also, the development of a robust proof-of-concept preclinical model can be costly because it may involve immunomodulation to match the human immune system.
• Following the strict regulatory guidelines for compliance in clinical trials is one of the main challenges that companies are facing. This, in turn, will challenge the market growth during the forecast period.

This cell and gene therapy market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global cell and gene therapy market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the cell and gene therapy market during the forecast period.

Who are the Major Cell and Gene Therapy Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

• Alnylam Pharmaceuticals Inc.
• Amgen Inc.
• Biogen Inc.
• bluebird bio Inc.
• Bristol Myers Squibb Co.
• Castle Creek Biosciences Inc.
• CORESTEM Inc.
• Cytori Therapeutics Inc.
• Dendreon Pharmaceuticals LLC.
• Ferring BV
• Gilead Sciences Inc.
• Helixmith Co. Ltd.
• Human Stem Cells Institute
• JCR Pharmaceticals Co. Ltd.
• Kolon TissueGene Inc.
• Novartis AG
• Orchard Therapeutics Plc
• Pfizer Inc.
• Sibiono GeneTech Co. Ltd.
• Vericel Corp.

 

This statistical study of the cell and gene therapy market encompasses successful business strategies deployed by the key vendors. The cell and gene therapy market is fragmented and the vendors are deploying growth strategies such as quality, price, market reach, and financial resources to compete in the market.

Product Insights and News

• Amgen Inc. - The unified segment focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics. 
• Amgen Inc. - The company offers cell and gene therapeutic solutions that can be incorporated into patients' own cytotoxic T cells to help them to recognize and fight cancer cells. 

To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The cell and gene therapy market forecast report offer in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Cell and Gene Therapy Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the cell and gene therapy market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for the Cell and Gene Therapy Market?

For more insights on the market share of various regions Request PDF Sample now!

41% of the market’s growth will originate from North America during the forecast period. The US is the key market for the cell and gene therapy market in North America. Market growth in this region will be slower than the growth of the market in Asia.

Huge investment in R&D activities for cell and gene therapy, especially in the US will facilitate the cell and gene therapy market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The outbreak of COVID-19 had a negative impact on the regional market. However, research institutes and healthcare facilities engaged in gene therapy have started developing new gene therapy products and treatments for individuals with cancer and other rare diseases in 2021. This, in turn, will boost the growth of the regional market during the forecast period.

What are the Revenue-generating Type Segments in the Cell and Gene Therapy Market?

To gain further insights on the market contribution of various segments Request PDF Sample

The cell and gene therapy market share growth by the cell therapy segment will be significant during the forecast period. Cell therapy is a type of treatment in which living cells are injected into a patient to cure different ailments. The demand for cell therapy treatment is increasing because their products can be used for personalized treatment. The therapeutic benefits of cell therapy products have encouraged companies to develop products from various cell lines such as stem cell-based products. Such factors of cell therapy will boost the market growth in the near future.

This report provides an accurate prediction of the contribution of all the segments to the growth of the cell and gene therapy market size and actionable market insights on the post-COVID-19 impact on each segment.

 

Cell and Gene Therapy Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 20.15%
Market growth 2022-2026	$9.97 billion
Market structure	Fragmented
YoY growth (%)	13.65
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 41%
Key consumer countries	US, Germany, UK, China, and Japan
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Alnylam Pharmaceuticals Inc., Amgen Inc., Biogen Inc., bluebird bio Inc., Bristol Myers Squibb Co., Castle Creek Biosciences Inc., CORESTEM Inc., Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC., Ferring BV, Gilead Sciences Inc., Helixmith Co. Ltd., Human Stem Cells Institute, JCR Pharmaceticals Co. Ltd., Kolon TissueGene Inc., Novartis AG, Orchard Therapeutics Plc, Pfizer Inc., Sibiono GeneTech Co. Ltd., and Vericel Corp.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Cell and Gene Therapy Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive cell and gene therapy market growth during the next five years
• Precise estimation of the cell and gene therapy market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the cell and gene therapy industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of cell and gene therapy market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch